Drug Profile

Iparomlimab/tuvonralimab - Sound Biologics

Alternative Names: Anti-PD-1/CTLA-4 MabPair; PSB-205; QL 1706

Latest Information Update: 15 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sound Biologics
Developer Fudan University; Qilu Hospital of Shandong University; Qilu Pharmaceutical; Sound Biologics; Tianjin Medical University Cancer Institute and Hospital
Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Registered Cervical cancer
Phase III Nasopharyngeal cancer; Non-small cell lung cancer
Phase II/III Liver cancer
Phase II Adenocarcinoma; Colorectal cancer; Endometrial cancer; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
Phase I/II Trophoblastic tumour
Phase I Solid tumours

08 Jul 2025 Fujian Cancer Hospital plans the phase II NICE-CC trial for Cervical cancer (Late-stage disease) in China (IV) (NCT07055399)
03 Jul 2025 Peking University Cancer Hospital & Institute plans a phase II trial for Squamous Cell Cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) (IV) in July 2025 (NCT07049185)
01 Jul 2025 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School plans a phase II trial for Gastric Cancer (Combination-therapy, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease), in July 2025 (NCT07045805)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com